$VOR
Vor Biopharma Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021188 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.277M $8.507M $7.520M
YoY Change 28.15% 13.13% 56.99%
% of Gross Profit
Research & Development $23.90M $21.92M $15.28M
YoY Change 55.85% 43.42% 70.9%
% of Gross Profit
Depreciation & Amortization $900.0K $800.0K $400.0K
YoY Change 50.0% 100.0% 33.33%
% of Gross Profit
Operating Expenses $32.17M $30.42M $22.80M
YoY Change 47.64% 33.43% 66.06%
Operating Profit -$32.17M -$30.42M -$22.80M
YoY Change 47.64% 33.43% 66.06%
Interest Expense $2.195M $1.989M $63.00K
YoY Change 1550.38% 3057.14% 530.0%
% of Operating Profit
Other Income/Expense, Net $2.195M $1.989M $63.00K
YoY Change 1550.38% 3057.14% 800.0%
Pretax Income -$29.98M -$28.43M -$22.74M
YoY Change 38.41% 25.05% 65.72%
Income Tax
% Of Pretax Income
Net Earnings -$29.98M -$28.43M -$22.74M
YoY Change 38.41% 25.05% 65.69%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.43 -$0.61
Diluted Earnings Per Share -$0.45 -$0.43 -$609.7K
COMMON SHARES
Basic Shares Outstanding 66.96M 66.37M 37.49M
Diluted Shares Outstanding 67.03M 66.27M 37.29M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $186.9M $210.2M $181.6M
YoY Change 23.7% 15.74% -30.84%
Cash & Equivalents $32.21M $42.46M $90.04M
Short-Term Investments $154.7M $167.7M $91.58M
Other Short-Term Assets $539.0K $459.0K $2.212M
YoY Change -76.44% -79.25% 2304.35%
Inventory
Prepaid Expenses $3.952M $6.239M $6.474M
Receivables
Other Receivables
Total Short-Term Assets $191.4M $216.9M $190.3M
YoY Change 20.49% 13.98% -28.53%
LONG-TERM ASSETS
Property, Plant & Equipment $11.46M $11.86M $11.77M
YoY Change -22.75% 0.76% 105.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.268M $2.791M $8.189M
YoY Change 37.02% -65.92% 217.16%
Total Long-Term Assets $59.59M $60.64M $43.97M
YoY Change -9.39% 37.91% 64.83%
TOTAL ASSETS
Total Short-Term Assets $191.4M $216.9M $190.3M
Total Long-Term Assets $59.59M $60.64M $43.97M
Total Assets $251.0M $277.5M $234.3M
YoY Change 11.74% 18.47% -20.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.648M $3.216M $1.255M
YoY Change 29.97% 156.25% -47.84%
Accrued Expenses $7.256M $5.485M $9.258M
YoY Change 15.43% -40.75% 110.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.72M $12.58M $18.15M
YoY Change 3.71% -30.68% 110.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $33.82M $34.74M $21.68M
YoY Change -9.52% 60.26% 26.77%
Total Long-Term Liabilities $33.82M $34.74M $21.68M
YoY Change -9.52% 60.26% 26.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.72M $12.58M $18.15M
Total Long-Term Liabilities $33.82M $34.74M $21.68M
Total Liabilities $46.54M $47.32M $39.82M
YoY Change -6.25% 18.82% 54.64%
SHAREHOLDERS EQUITY
Retained Earnings -$280.6M -$250.7M -$152.9M
YoY Change 60.8% 63.97% 103.96%
Common Stock $485.5M $481.0M $348.4M
YoY Change 38.39% 38.08% 1.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $204.5M $230.2M $194.4M
YoY Change
Total Liabilities & Shareholders Equity $251.0M $277.5M $234.3M
YoY Change 11.74% 18.47% -20.03%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$29.98M -$28.43M -$22.74M
YoY Change 38.41% 25.05% 65.69%
Depreciation, Depletion And Amortization $900.0K $800.0K $400.0K
YoY Change 50.0% 100.0% 33.33%
Cash From Operating Activities -$24.10M -$24.27M -$22.90M
YoY Change -3.57% 5.96% 29.78%
INVESTING ACTIVITIES
Capital Expenditures $399.0K $94.00K $2.011M
YoY Change -106.84% -95.33% 71.73%
Acquisitions
YoY Change
Other Investing Activities $14.04M $6.592M -$5.044M
YoY Change 348.5% -230.69%
Cash From Investing Activities $13.64M $6.498M -$7.055M
YoY Change -604.77% -192.1% 502.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 218.0K 2.519M 200.0K
YoY Change -63.91% 1159.5% -99.91%
NET CHANGE
Cash From Operating Activities -24.10M -24.27M -22.90M
Cash From Investing Activities 13.64M 6.498M -7.055M
Cash From Financing Activities 218.0K 2.519M 200.0K
Net Change In Cash -10.24M -15.25M -29.76M
YoY Change -62.19% -48.75% -113.9%
FREE CASH FLOW
Cash From Operating Activities -$24.10M -$24.27M -$22.90M
Capital Expenditures $399.0K $94.00K $2.011M
Free Cash Flow -$24.50M -$24.36M -$24.92M
YoY Change 27.87% -2.22% 32.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57706000
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001817229
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39979
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
VOR BIOPHARMA INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1591163
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Cambridgepark Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 101
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02140
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
655-6580
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
VOR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66956800
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42455000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
167745000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
172539000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6239000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4368000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
459000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2337000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
216898000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
236950000
CY2023Q1 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222217000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
230215000
CY2022Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11856000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12634000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43575000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44444000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2791000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2925000
CY2023Q1 us-gaap Assets
Assets
277533000
CY2022Q4 us-gaap Assets
Assets
299366000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3216000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1772000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5485000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7889000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3713000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3272000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
165000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
186000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12579000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13119000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34739000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35640000
CY2023Q1 us-gaap Liabilities
Liabilities
47318000
CY2022Q4 us-gaap Liabilities
Liabilities
48759000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66991060
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66079597
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66934897
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65996138
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
481032000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
473587000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-174000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-770000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250650000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
250607000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
277533000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1953000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
920000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299366000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21915000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15280000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8507000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7520000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
30422000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
22800000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30422000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22800000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1989000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
63000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1989000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
63000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28433000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22737000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66265703
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66265703
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37293438
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37293438
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
596000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1072000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
596000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1072000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27837000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23809000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
250607000
CY2023Q1 vor Stock Issued During Period Value Stock Options Vested Of Restricted Stock Units And Exercised
StockIssuedDuringPeriodValueStockOptionsVestedOfRestrictedStockUnitsAndExercised
-340000
CY2023Q1 vor Stock Issued During Period Value Issuance Of Common Stock From Open Market Sales Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockFromOpenMarketSalesAgreement
3717000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4068000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
596000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28433000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
230215000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
216263000
CY2022Q1 vor Stock Issued During Period Value Stock Options Vested And Exercised
StockIssuedDuringPeriodValueStockOptionsVestedAndExercised
247000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1746000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1072000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22737000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
194447000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-28433000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-22737000
CY2023Q1 us-gaap Depreciation
Depreciation
837000
CY2022Q1 us-gaap Depreciation
Depreciation
426000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4068000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1746000
CY2023Q1 vor Interest Amortization Accretion On Marketable Securities
InterestAmortizationAccretionOnMarketableSecurities
1202000
CY2022Q1 vor Interest Amortization Accretion On Marketable Securities
InterestAmortizationAccretionOnMarketableSecurities
-65000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1544000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-727000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1740000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-88000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-722000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-134000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
135000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24268000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22904000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
23408000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5044000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30000000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2011000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6498000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7055000
CY2023Q1 vor Payment Of Issuance Costs Related To Underwritten Public Offering And Concurrent Private Placement
PaymentOfIssuanceCostsRelatedToUnderwrittenPublicOfferingAndConcurrentPrivatePlacement
717000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3622000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
400000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2519000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
200000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15251000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29759000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60119000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122214000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44868000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92455000
CY2022Q1 vor Lease Incentive Paid By Landlord
LeaseIncentivePaidByLandlord
1509000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
270000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6377000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3539000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42455000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90042000
CY2023Q1 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2022Q1 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44868000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92455000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
167745000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
173309000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
770000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
172539000
CY2023Q1 vor Debt Securities Available For Sale Change In Present Values Expense Reversal
DebtSecuritiesAvailableForSaleChangeInPresentValuesExpenseReversal
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of the Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vor Biopharma Inc. (the “Company”) is a clinical-stage cell and genome engineering company that combines a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. The Company’s proprietary platform leverages its expertise in hematopoietic stem cell (“HSC”) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company is headquartered in Cambridge, Massachusetts. The Company was incorporated on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 30, 2015</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, geopolitical tensions, adverse macroeconomic conditions and the need to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company believes that its existing cash, cash equivalents and marketable securities at March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date the financial statements are issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2015-12-30
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: accrued expenses and research and development expenses.</span></p>
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
167919000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
180000
CY2023Q1 vor Fair Value Assets Level1 To Level2 Transferred Amount
FairValueAssetsLevel1ToLevel2TransferredAmount
0
CY2023Q1 vor Fair Value Assets Level2 To Level1 Transferred Amount
FairValueAssetsLevel2ToLevel1TransferredAmount
0
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17302000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17244000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5446000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4610000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11856000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12634000
CY2023Q1 us-gaap Depreciation
Depreciation
800000
CY2022Q1 us-gaap Depreciation
Depreciation
400000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1576000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4408000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1461000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1701000
CY2023Q1 vor Clinical Expenses Current
ClinicalExpensesCurrent
1070000
CY2022Q4 vor Clinical Expenses Current
ClinicalExpensesCurrent
532000
CY2023Q1 vor Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
627000
CY2022Q4 vor Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
569000
CY2023Q1 vor Manufacturing Expenses Current
ManufacturingExpensesCurrent
572000
CY2022Q4 vor Manufacturing Expenses Current
ManufacturingExpensesCurrent
328000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
179000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
351000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5485000
CY2022Q1 us-gaap Lease Cost
LeaseCost
1261000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7889000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1543219
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1818298
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.53
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.84
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
19900000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
56162
CY2023Q1 vor Share Based Compensation Arrangement By Share Based Payment Award Option Unvested Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionUnvestedExercisedInPeriodWeightedAverageExercisePrice
1.36
CY2023Q1 vor Proceeds From Stock Unvested Option Exercised
ProceedsFromStockUnvestedOptionExercised
100000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4068000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1746000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1953000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
920000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
597000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
341000
CY2023Q1 us-gaap Lease Cost
LeaseCost
2550000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43575000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44444000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3713000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3272000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34739000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35640000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
38452000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
38912000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1544000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
727000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
270000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6377000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28433000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22737000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66265703
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66265703
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37293438
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37293438
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61

Files In Submission

Name View Source Status
vor-20230331_lab.xml Edgar Link unprocessable
vor-20230331_def.xml Edgar Link unprocessable
vor-20230331_pre.xml Edgar Link unprocessable
vor-20230331_cal.xml Edgar Link unprocessable
0000950170-23-021188-index-headers.html Edgar Link pending
0000950170-23-021188-index.html Edgar Link pending
0000950170-23-021188.txt Edgar Link pending
0000950170-23-021188-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vor-20230331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
vor-20230331.xsd Edgar Link pending
vor-ex10_1.htm Edgar Link pending
vor-ex31_1.htm Edgar Link pending
vor-ex31_2.htm Edgar Link pending
vor-ex32_1.htm Edgar Link pending
vor-20230331_htm.xml Edgar Link completed